Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Profile of alisporivir and its potential in the treatment of hepatitis C.

Drug design, development and therapy - 1 Jan 2013

Gallay Philippe A, Lin Kai

Abstract excerpt

Two classes of hepatitis C antiviral agents currently exist, i.e., direct-acting antivirals and host-targeting antivirals. Direct-acting antivirals target viral proteins including NS3/NS4A protease, NS5B polymerase and NS5A protein, while host-targeting antivirals target various host proteins critical for replication of the hepatitis C virus (HCV). Alisporivir is the most advanced host-targeting antiviral in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cyclosporine
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C

Share to Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 23440335
DOI: 10.2147/DDDT.S30946
PMCID: PMC3578503

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Profile of alisporivir and its potential in the treatment of hepatitis C.PMID 23440335Read ↗

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).Semantic proximity Read ↗

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.Semantic proximity Read ↗

Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.Semantic proximity Read ↗

A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility.Semantic proximity Read ↗

Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.Semantic proximity Read ↗

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.Semantic proximity Read ↗

A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.Semantic proximity Read ↗

Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agentsSemantic proximity Read ↗

In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.Semantic proximity Read ↗

Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity.Semantic proximity Read ↗

DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5ASemantic proximity Read ↗

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.